Antagonist Protocol in IVF

Woman's Health University Hospital, Egypt

Status and phase: Unknown; Phase 2

Conditions: Infertility

Treatments: Drug: Gonadotropins releasing hormone antagonist

Study type: Interventional

Funder types: Other

Identifiers

NCT02335736

AA2015

Details and patient eligibility

About

The antagonist protocol in a novel method of stimulation in the in vitro fertilization (IVF) patients. It has been tried in poor responders, polycystic ovary (PCO) patients and normal females undergoing IVF. Can it be used with the same efficacy in all patients?

Enrollment: 200 estimated patients

Sex: Female

Ages: 20 to 44 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• age: 20- 44 years
• Poor responder females according to Bologna criteria
• Polycystic ovarian disease females according to Rotterdam criteria
• Females with infertility causes other than poor responders, or PCO; male factor or tubal block

Exclusion criteria

• refusal to get enrolled in the study
• cases of infertility due to severe male factor

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

200 participants in 3 patient groups

Normal

Active Comparator group

Description:

Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC.

Treatment:

Drug: Gonadotropins releasing hormone antagonist

Poor responders

Active Comparator group

Description:

Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC

Treatment:

Drug: Gonadotropins releasing hormone antagonist

Polycystic ovarian disease

Active Comparator group

Description:

Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant(Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC

Treatment:

Drug: Gonadotropins releasing hormone antagonist